Comment on

• Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories.

  Baehner FL, Achacoso N, Maddala T, Shak S, Quesenberry CP Jr, Goldstein LC, Gown AM, Habel LA. Baehner FL, et al. J Clin Oncol. 2010 Oct 1;28(28):4300-6. doi: 10.1200/JCO.2009.24.8211. Epub 2010 Aug 9. J Clin Oncol. 2010. PMID: 20697093
• Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer.

  Hammond ME, Hayes DF, Wolff AC. Hammond ME, et al. J Clin Oncol. 2011 May 20;29(15):e458. doi: 10.1200/JCO.2011.35.2245. Epub 2011 Apr 18. J Clin Oncol. 2011. PMID: 21502545 No abstract available.
• High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study.

  Dabbs DJ, Klein ME, Mohsin SK, Tubbs RR, Shuai Y, Bhargava R. Dabbs DJ, et al. J Clin Oncol. 2011 Nov 10;29(32):4279-85. doi: 10.1200/JCO.2011.34.7963. Epub 2011 Oct 11. J Clin Oncol. 2011. PMID: 21990395
• Quantitative reverse transcriptase polymerase chain reaction and the Oncotype DX test for assessment of human epidermal growth factor receptor 2 status: time to reflect again?

  Bartlett JM, Starczynski J. Bartlett JM, et al. J Clin Oncol. 2011 Nov 10;29(32):4219-21. doi: 10.1200/JCO.2011.37.5824. Epub 2011 Oct 11. J Clin Oncol. 2011. PMID: 21990408 No abstract available.